{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:55Z","timestamp":1776988795089,"version":"3.51.4"},"reference-count":16,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T00:00:00Z","timestamp":1449964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009666\u201015"],"award-info":[{"award-number":["T32CA009666\u201015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,8]]},"abstract":"\n Objective<\/jats:title>\n \n To explore the efficacy and safety of pazopanib in a \u2018real\u2010world\u2019 setting in unselected patients, as data regarding unselected patients with metastatic clear\u2010cell renal cell carcinoma (cc\n RCC<\/jats:styled-content>\n ) treated with first\u2010line pazopanib are limited.\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n We reviewed records of patients with metastatic cc\n RCC<\/jats:styled-content>\n treated with first\u2010line pazopanib from 1 November 2009 through to 1 November 2012. Cox models were fitted to evaluate the association of progression\u2010free survival (\n PFS<\/jats:styled-content>\n ) and overall survival (\n OS<\/jats:styled-content>\n ) with patient co\u2010variables.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In all, 88 patients were identified; 74 were evaluable for response: two (3%) had a complete response, 27 (36%) a partial response, 36 (49%) had stable disease and nine (12%) had progressive disease. The median\n PFS<\/jats:styled-content>\n was 13.7 months [95% confidence interval (\n CI<\/jats:styled-content>\n ) 8.7\u201318.3].\n PFS<\/jats:styled-content>\n was correlated with a Karnofsky Performance Status score of <80 [hazard ratio (\n HR<\/jats:styled-content>\n ) 3.26,\n P<\/jats:italic>\n < 0.001] and serum lactate dehydrogenase of >1.5 \u00d7 upper limit of normal (\n HR<\/jats:styled-content>\n 3.25,\n P<\/jats:italic>\n = 0.014). The median\n OS<\/jats:styled-content>\n was 29.1 months (95%\n CI<\/jats:styled-content>\n 20.2\u2013not reached). The\n OS<\/jats:styled-content>\n was correlated with brain metastasis (\n HR<\/jats:styled-content>\n 2.55,\n P<\/jats:italic>\n = 0.009), neutrophilia (\n HR<\/jats:styled-content>\n 1.179,\n P<\/jats:italic>\n = 0.018), and anaemia (\n HR<\/jats:styled-content>\n 3.51,\n P<\/jats:italic>\n < 0.001). There were no treatment\u2010related deaths. In all, 53 patients received second\u2010line therapy [vascular endothelial growth factor receptor tyrosine kinase inhibitors (\n VEGFR<\/jats:styled-content>\n \u2010\n TKI<\/jats:styled-content>\n ) in 22 patients, mammalian target of rapamycin inhibitors (\n mTOR<\/jats:styled-content>\n i) in 22 patients, and other therapy in nine patients]; the median\n PFS<\/jats:styled-content>\n was 8.6 months (95%\n CI<\/jats:styled-content>\n 3.3\u201325.7) with\n VEGFR<\/jats:styled-content>\n \u2010\n TKI<\/jats:styled-content>\n and 5 months (95%\n CI<\/jats:styled-content>\n 3.5\u201315.2) with\n mTOR<\/jats:styled-content>\n i (\n P<\/jats:italic>\n = 0.41); the median\n OS<\/jats:styled-content>\n was 19.9 months (95%\n CI<\/jats:styled-content>\n 12.9\u2013not reached) and 14.2 months (95%\n CI<\/jats:styled-content>\n 8.1\u2013not reached), from initiation of second\u2010line\n VEGFR<\/jats:styled-content>\n \u2010\n TKI<\/jats:styled-content>\n or\n mTOR<\/jats:styled-content>\n i, respectively (\n P<\/jats:italic>\n = 0.37).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In this retrospective study, first\u2010line pazopanib confirmed its efficacy in metastatic cc\n RCC<\/jats:styled-content>\n . Trends for longer\n PFS<\/jats:styled-content>\n and\n OS<\/jats:styled-content>\n were seen with\n VEGFR<\/jats:styled-content>\n \u2010\n TKI<\/jats:styled-content>\n compared with\n mTOR<\/jats:styled-content>\n i after first\u2010line pazopanib.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.13374","type":"journal-article","created":{"date-parts":[[2015,11,17]],"date-time":"2015-11-17T07:38:43Z","timestamp":1447745923000},"page":"264-271","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes of unselected patients with metastatic clear\u2010cell renal cell carcinoma treated with first\u2010line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience"],"prefix":"10.1111","volume":"118","author":[{"given":"Marc R.","family":"Matrana","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharakeswara","family":"Bathala","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Duran","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Shetty","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Hematology and Oncology Fellowship David Geffen School of Medicine University of California Los Angeles Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purnima","family":"Teegavarapu","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarathi","family":"Kalra","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Division of Emergency Medicine Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Division of Quantitative Sciences The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Programs The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Corn","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.179"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25836"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0293-x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488411797189398"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8267"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.132"},{"key":"e_1_2_7_11_1","unstructured":"GalvisV ChowS ThistlethwaiteFC.Clinical practice outcomes of patients treated with pazopanib for metastatic renal cell cancer (mRCC) \u2013 6 year experience at a referral centre in Manchester UK. European Cancer Congress Amsterdam The Netherlands 2013. Abstract 2763"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.11.001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331190"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.07.004"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-21858-3_15"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.003"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13374","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:05:25Z","timestamp":1761746725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,13]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/bju.13374"],"URL":"https:\/\/doi.org\/10.1111\/bju.13374","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,13]]},"assertion":[{"value":"2015-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}